市場調查報告書

按藥物類型,疾病指示□□,分佈渠道,成分,區域大小,佔有率,前景和機會分析劃分的青光眼滴眼劑市場

Glaucoma Eye Drops Market, by Drug Type, by Disease Indication, By Distribution Channel, by Composition, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版商 Coherent Market Insights 商品編碼 952807
出版日期 內容資訊 英文 144 Pages
商品交期: 2-3個工作天內
價格
按藥物類型,疾病指示□□,分佈渠道,成分,區域大小,佔有率,前景和機會分析劃分的青光眼滴眼劑市場 Glaucoma Eye Drops Market, by Drug Type, by Disease Indication, By Distribution Channel, by Composition, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
出版日期: 2020年07月09日內容資訊: 英文 144 Pages
簡介

由於青光眼的患病率上升,預計在預測期內,全球青光眼滴眼劑市場將顯著增長。根據國際預防失明機構2015年的調查,到2020年,估計有300萬人患有失明,估計有8000萬人患有青光眼。自2010年以來,這大約增加了2000萬。快速增長的人口老齡化是增加青光眼患病率的關鍵因素之一,並有望推動市場增長。

本報告調查了青光眼滴眼劑市場,並探討了市場機會和趨勢,增長和限制,監管情況,按藥物類型/疾病指示/分佈渠道/組成/地區,競爭格局,我們提供諸如主要公司簡介之類的信息。

目錄

第1章調查目的和假設

第2章市場概述

  • 報告概述
    • 市場定義和範圍
  • 執行摘要
    • 市場細分:按藥物類型
    • 市場細分:按疾病指示
    • 市場細分:按分銷渠道
    • 市場細分:按構成
    • 市場細分:按地區
  • 相干機會圖(COM)

第3章市場動態,法規,趨勢分析

  • 市場動態
    • 生長因子
    • 抑制因子
    • 市場機會
  • 影響分析
  • 市場趨勢
  • 監管方案
  • 管道分析
  • 產品認可
  • 產品發佈
  • PEST分析
  • 價格分析
  • 不含防腐劑和防腐劑的青光眼治療液

第4章Covid-19的影響分析

  • 供應方分析
  • 需求側分析
  • 對醫療保健行業的影響

第5章市場分析:按藥物類型

  • 簡介
  • 前列腺素類似物
  • Beta阻斷劑
  • Alpha激動劑
  • 碳酸酐□抑製劑(CAI)
  • 伴隨藥物
  • 其他(激素激□抑製劑,膽鹼能藥物)

第6章市場分析:按疾病指示

  • 簡介
  • 閉角型青光眼
  • 開角型青光眼

第7章市場分析:分銷渠道

  • 簡介
  • 醫院藥房
  • 零售藥房
  • 在線藥房

第8章市場分析:按構成

  • 簡介
  • 無防腐劑
  • 苯扎氯銨(BAK)防腐劑
  • 基於非苯扎氯銨(BAK)的防腐劑

第9章按地區進行市場分析

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 非洲
  • 中東

第10章競爭情況

  • 公司簡介
    • Merck & Co., Inc.
    • Allergan Plc.
    • Novartis AG
    • Teva Pharmaceutical Industry
    • Pfizer, Inc.
    • Bausch & Lomb Inc.
    • Inotek Pharmaceutical
    • Jadran-galenski laboratorij d.d.
    • Aerie Pharmaceutical
    • Mylan N.V

第11章的部分

目錄

Glaucoma may occur among the people with or without diabetes. Moreover, people with diabetic retinopathy have an increased risk of glaucoma. The condition is associated with abnormal blood vessel growth, which can result in retinopathy and leads to blockage of natural drainage of the eye. Rapidly increasing geriatric population is one of the important factors for increasing prevalence of glaucoma, which in turn is projected to drive growth of the glaucoma therapeutics market in near future. For instance, according to the International Diabetes Foundation (IDF) 2017 statistics, the number of people with diabetes aged between 20 to 79 years are increasing worldwide.

Market Dynamics

The global glaucoma eye drops market is expected to witness significant growth during the forecast period owing to the increasing prevalence of glaucoma, For instance, according to the International Agency for the Prevention of Blindness, in 2015, an estimated 3 million people suffered from blindness due to glaucoma in the U.S. Furthermore, as per the same source, it is estimated that by 2020 around 80 million people will suffer from glaucoma, with an increase of about 20 million from 2010 globally.

Key features of the study:

  • This report provides in-depth analysis of the global glaucoma eye drops market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global glaucoma eye drops market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Merck & Co., Inc., Allergan Plc., Novartis AG., Teva Pharmaceutical Industry, Pfizer, Inc., Bausch & Lomb Inc., Inotek Pharmaceutical, Jadran-galenski laboratorij d.d., Aerie Pharmaceutical, and Mylan N.V.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, government initiatives, technological upgradation, market expansion, and marketing tactics
  • The global glaucoma eye drops market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for glaucoma eye drops, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

  • Global Glaucoma Eye Drops Market, By Drug Type:
    • Prostaglandin analogs
    • Beta blockers
    • Alpha agonists
    • Carbonic Anhydrase Inhibitors (CAIs)
    • Combined Medications
    • Others (rho-kinase inhibitor, Cholinergic agonist)
  • Global Glaucoma Eye Drops Market, By Disease Indication:
    • Angle-closure Glaucoma
    • Open-angle Glaucoma
  • Global Glaucoma Eye Drops Market, By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
  • Global Glaucoma Eye Drops Market, By Composition:
    • Preservative Free
    • BAK-Based
    • Non BAK-Based Preservatives
  • Global Glaucoma Eye Drops Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
      • By Drug Type:
    • Prostaglandin analogs
    • Beta blockers
    • Alpha agonists
    • Carbonic Anhydrase Inhibitors (CAIs)
    • Combined Medications
    • Others (rho-kinase inhibitor, Cholinergic agonist)
      • By Disease Indication:
    • Angle-closure Glaucoma
    • Open-angle Glaucoma
      • By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
      • By Composition:
    • Preservative Free
    • BAK-Based
    • Non BAK-Based Preservatives
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
      • By Drug Type:
    • Prostaglandin analogs
    • Beta blockers
    • Alpha agonists
    • Carbonic Anhydrase Inhibitors (CAIs)
    • Combined Medications
    • Others (rho-kinase inhibitor, Cholinergic agonist)
      • By Disease Indication:
    • Angle-closure Glaucoma
    • Open-angle Glaucoma
      • By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
      • By Composition:
    • Preservative Free
    • BAK-Based
    • Non BAK-Based Preservatives
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
      • By Drug Type:
    • Prostaglandin analogs
    • Beta blockers
    • Alpha agonists
    • Carbonic Anhydrase Inhibitors (CAIs)
    • Combined Medications
    • Others (rho-kinase inhibitor, Cholinergic agonist)
      • By Disease Indication:
    • Angle-closure Glaucoma
    • Open-angle Glaucoma
      • By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
      • By Composition:
    • Preservative Free
    • BAK-Based
    • Non BAK-Based Preservatives
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
      • By Drug Type:
    • Prostaglandin analogs
    • Beta blockers
    • Alpha agonists
    • Carbonic Anhydrase Inhibitors (CAIs)
    • Combined Medications
    • Others (rho-kinase inhibitor, Cholinergic agonist)
      • By Disease Indication:
    • Angle-closure Glaucoma
    • Open-angle Glaucoma
      • By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
      • By Composition:
    • Preservative Free
    • BAK-Based
    • Non BAK-Based Preservatives
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
      • By Drug Type:
    • Prostaglandin analogs
    • Beta blockers
    • Alpha agonists
    • Carbonic Anhydrase Inhibitors (CAIs)
    • Combined Medications
    • Others (rho-kinase inhibitor, Cholinergic agonist)
      • By Disease Indication:
    • Angle-closure Glaucoma
    • Open-angle Glaucoma
      • By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
      • By Composition:
    • Preservative Free
    • BAK-Based
    • Non BAK-Based Preservatives
    • Africa
      • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
      • By Drug Type:
    • Prostaglandin analogs
    • Beta blockers
    • Alpha agonists
    • Carbonic Anhydrase Inhibitors (CAIs)
    • Combined Medications
    • Others (rho-kinase inhibitor, Cholinergic agonist)
      • By Disease Indication:
    • Angle-closure Glaucoma
    • Open-angle Glaucoma
      • By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
      • By Composition:
    • Preservative Free
    • BAK-Based
    • Non BAK-Based Preservatives
  • Company Profiles
    • Merck & Co., Inc.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Allergan Plc.
    • Novartis AG
    • Teva Pharmaceutical Industry
    • Pfizer, Inc.
    • Bausch & Lomb Inc.
    • Inotek Pharmaceutical
    • Jadran-galenski laboratorij d.d.
    • Aerie Pharmaceutical
    • Mylan N.V
  • "*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Disease Indication
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Composition
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Regulatory Scenario
  • Pipeline Analysis
  • Product Approvals
  • Product Launches
  • Pest Analysis
  • Pricing Analysis
  • Preservative and preservative-free glaucoma treatment solutions

4. Impact Analysis of Covid-19

  • Supply side Analysis
  • Demand Side Analysis
  • Impact on Healthcare Industry

5. Global Glaucoma Eye Drops Market, By Drug Type, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Prostaglandin analogs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Beta blockers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Alpha agonists
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Carbonic Anhydrase Inhibitors (CAIs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Combined Medications
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Others (rho-kinase inhibitor, Cholinergic agonist)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

6. Global Glaucoma Eye Drops Market, By Disease Indication, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Angle-closure Glaucoma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Open-angle Glaucoma
    • Introduction
    • Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

7. Global Glaucoma Eye Drops Market, By Distribution Channel , 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospital Pharmacy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Retail Pharmacy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Online Pharmacy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

8. Global Glaucoma Eye Drops Market, By Composition, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Preservative Free
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • BAK-Based
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Non BAK-Based Preservatives
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

9. Global Glaucoma Eye Drops Market, By Region, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2027
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel , 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Composition, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel , 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Composition, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel , 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Composition, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel , 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Composition, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel , 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Composition, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel , 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Composition, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East

10. Competitive Landscape

  • Company Profiles
    • Merck & Co., Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Allergan Plc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Teva Pharmaceutical Industry
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Bausch & Lomb Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Inotek Pharmaceutical
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Jadran-galenski laboratorij d.d.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Aerie Pharmaceutical
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Mylan N.V
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

11. Section

  • References
  • Research Methodology
  • About us and Sales Contact